TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26006197

Group type: EXPERIMENTAL
Intervention: 2 g/kg PEG powder (17 g in 240 mL water or another beverage) and 5 mg bisacodyl suppository (BD) the day before colonoscopy
Number of subjects: 100

Group type: COMPARATOR
Intervention: 1.5 g/kg PEG with fruit juices for two days and 5 mg bisacodyl suppository (BD) for two days before colonoscopy
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: One-day PEG plus bisacodyl regimen
Number of subjects: 100

Group type: COMPARATOR
Intervention: Two-day PEG plus bisacodyl regimen
Number of subjects: 100
Study: 22659022

Group type: EXPERIMENTAL
Intervention: tDCS(anodal) over left SMA
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: tDCS(anodal) over left M1
Number of subjects: 36

Group type: COMPARATOR
Intervention: tDCS(sham)
Number of subjects: 36
Study: 21735348

Group type: EXPERIMENTAL
Intervention: Experimental physicians trained in upfront agenda setting through the Establishing Focus Protocol, including two hours of training and two hours of coaching per week for four consecutive weeks.
Number of subjects: 1460

Group type: COMPARATOR
Intervention: Control group (not explicitly defined in the abstract).
Number of subjects: 1460
Study: 19731300

Group type: EXPERIMENTAL
Intervention: Active cluster LEDT (69 LEDs with wavelengths 660/850 nm, 10/30 mW, 30 seconds total irradiation time, 41.7 J of total energy irradiated)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Active cluster LEDT
Number of subjects: 10
Study: 17046506

Group type: EXPERIMENTAL
Intervention: Ending Violence curriculum (three-class-session prevention program focused on legal issues)
Number of subjects: 0
Study: 14709121

Group type: EXPERIMENTAL
Intervention: Whole-body skin examinations by GPs
Number of subjects: 3100

Group type: EXPERIMENTAL
Intervention: Factors associated with increased likelihood of skin examination
Number of subjects: 3100
Study: 11782286

Group type: EXPERIMENTAL
Intervention: High quality paper
Number of subjects: 389

Group type: COMPARATOR
Intervention: Standard quality paper
Number of subjects: 389
Study: 9426791

Group type: EXPERIMENTAL
Intervention: QSC + EBF + SBF
Number of subjects: 426

Group type: COMPARATOR
Intervention: QSC
Number of subjects: 426

Group type: EXPERIMENTAL
Intervention: QSC + EBF
Number of subjects: 426

Group type: EXPERIMENTAL
Intervention: Genetic susceptibility feedback
Number of subjects: 426
Study: 8324855

Group type: COMPARATOR
Intervention: Height-based dosing method
Number of subjects: 7152

Group type: COMPARATOR
Intervention: Physical appearance dosing method
Number of subjects: 7152
Study: 3719535

Group type: EXPERIMENTAL
Intervention: 3-day fecal occult blood (FOB) testing
Number of subjects: 26975

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 26975

Group type: EXPERIMENTAL
Intervention: Guaiac (Hemoccult) and immunologic (Feca EIA) FOB tests
Number of subjects: 26975

Group type: EXPERIMENTAL
Intervention: Fecal occult blood testing
Number of subjects: 26975
Study: 29735039

Group type: EXPERIMENTAL
Intervention: Sugar-reduced nectars with health claim
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Sugar-reduced nectars with hedonic claim
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Sugar-reduced nectars with no claims
Number of subjects: 206

Group type: COMPARATOR
Intervention: Control product without sugar reduction
Number of subjects: 206
Study: 25852131

Group type: EXPERIMENTAL
Intervention: Electrostimulation plus low molecular weight heparin and below-knee compression stockings (Group 1)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Low molecular weight heparin and below-knee compression stockings alone (Group 2, control group)
Number of subjects: 30
Study: 24662896

Group type: EXPERIMENTAL
Intervention: Intervention group (child care centers with healthy menu changes and family-based education)
Number of subjects: 307

Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 307

Group type: COMPARATOR
Intervention: Control group (attention control program)
Number of subjects: 307
Study: 22202544

Group type: EXPERIMENTAL
Intervention: Music group
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Noise-cancelling headphones group
Number of subjects: 88

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 88
Study: 20497292

Group type: EXPERIMENTAL
Intervention: Video education
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control
Number of subjects: 42
Study: 18031471

Group type: EXPERIMENTAL
Intervention: Mirtazapine (30 mg daily)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Nortriptyline (50 mg daily)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Mirtazapine and Nortriptyline
Number of subjects: 40
Study: 16098680

Group type: EXPERIMENTAL
Intervention: Valproate
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study: 11915576

Group type: EXPERIMENTAL
Intervention: 10 mg MPA
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 20 mg MPA
Number of subjects: 36
Study: 10736332

Group type: EXPERIMENTAL
Intervention: Background diets (basic foods diet, self‐selected diet at specified times, self‐selected diet eaten ad libitum)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Soy foods (tofu, tempeh, cooked soybeans, texturized vegetable protein)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Isoflavone doses of 0.8‐1.4 mg/kg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Isoflavone bioavailability
Number of subjects: 8
Study: 9344322

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy for nonextremity sarcomas
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy
Number of subjects: 0
Study: 1398472

Group type: EXPERIMENTAL
Intervention: Recombinant human GH (rhGH) treatment for 6 months
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 21
Study: 3998766

Group type: EXPERIMENTAL
Intervention: Synthetic thymosin-alpha 1 (loading dose regimen)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Synthetic thymosin-alpha 1 (twice‐weekly schedule)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Synthetic thymosin-alpha 1
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 30146344

Group type: EXPERIMENTAL
Intervention: VR942 0.5 mg
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: VR942 10 mg
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: VR942 20 mg
Number of subjects: 85

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: VR942 (all doses)
Number of subjects: 85
Study: 26834046

Group type: EXPERIMENTAL
Intervention: Active encouragement for diagnostic testing and treatment
Number of subjects: 350

Group type: COMPARATOR
Intervention: Usual care according to the Dutch guideline on urinary incontinence
Number of subjects: 350
Study: 24627552

Group type: EXPERIMENTAL
Intervention: Nicotine patches
Number of subjects: 402

Group type: COMPARATOR
Intervention: Placebo patches
Number of subjects: 402
Study: 23291139

Group type: EXPERIMENTAL
Intervention: Paclitaxel combined with S-1
Number of subjects: 240

Group type: COMPARATOR
Intervention: Paclitaxel combined with fluorouracil
Number of subjects: 240
Study: 19962730

Group type: EXPERIMENTAL
Intervention: Intranasal desmopressin spray (40 microg) plus diclofenac sodium suppository (100 mg)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Diclofenac sodium suppository (100 mg) plus placebo spray (normal saline 0.9%)
Number of subjects: 150
Study: 18375325

Group type: COMPARATOR
Intervention: Standard tranexamic acid dosing regimen (10 mg/kg over 20 minutes, followed by 1 mg/kg/h)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: New tranexamic acid dosing schedule
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: New dosing protocol for tranexamic acid
Number of subjects: 20
Study: 15972907

Group type: EXPERIMENTAL
Intervention: TKR with polyradial femur
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: TKR with single radius design
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: TKR with cam-post mechanism
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: TKR without cam-post mechanism
Number of subjects: 55

Group type: COMPARATOR
Intervention: Normal knees
Number of subjects: 55
Study: 12795227

Group type: EXPERIMENTAL
Intervention: Tianbaokang Injection
Number of subjects: 70

Group type: COMPARATOR
Intervention: Contrast group (not specified intervention)
Number of subjects: 70
Study: 10392941

Group type: EXPERIMENTAL
Intervention: Stent placement indicated based on different hemodynamic criteria
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Residual mean pressure gradient of > 5 and < 10 mm Hg
Number of subjects: 136
Study: 8907442

Group type: EXPERIMENTAL
Intervention: StairMaster training
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Treadmill training
Number of subjects: 12
Study: 31054935

Group type: EXPERIMENTAL
Intervention: Taurolidine-citrate (T-C) solution
Number of subjects: 86
Study: 28220514

Group type: EXPERIMENTAL
Intervention: Fresh FMT product
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Frozen FMT product
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Lyophilised FMT product
Number of subjects: 72

Group type: COMPARATOR
Intervention: All groups
Number of subjects: 72
Study: 27003917

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (1 μg/kg load followed by a continuous infusion of 0.5 μg/kg/h)
Number of subjects: 142

Group type: COMPARATOR
Intervention: Saline (control group)
Number of subjects: 142
Study: 25216660

Group type: EXPERIMENTAL
Intervention: Nonrestorative caries treatment (NRCT; no caries removal, opening up the cavity, teaching brushing and fluoride application)
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: Conventional restorations (CR; complete caries removal and compomer restoration)
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: Hall technique (HT; no caries removal, sealing in with stainless steel crowns)
Number of subjects: 169

Group type: COMPARATOR
Intervention: NRCT
Number of subjects: 169

Group type: COMPARATOR
Intervention: CR
Number of subjects: 169

Group type: COMPARATOR
Intervention: HT
Number of subjects: 169
Study: 21908204

Group type: EXPERIMENTAL
Intervention: Alpha-lipoic acid (ALA) supplementation (600 mg daily for 8 weeks)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study: 18810386

Group type: EXPERIMENTAL
Intervention: Minimally invasive Watson‐Jones approach (MIS group)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Transgluteal Bauer approach (control group)
Number of subjects: 40
Study: 15729082

Group type: EXPERIMENTAL
Intervention: Risperidone (3.6±1.5 mg/day)
Number of subjects: 40
Study: 12793117

Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT)
Number of subjects: 350

Group type: COMPARATOR
Intervention: Control group (pharmacological therapy alone)
Number of subjects: 350
Study: 11253475

Group type: EXPERIMENTAL
Intervention: Platelet activation markers (CD62) measured on the 1st (2.6 +/‐ 1.4%), 3rd (3.5 +/‐ 2.3%), and 7th (3.0 +/‐ 2.0%) day after stroke onset
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Platelet activation markers (CD63) measured on the 1st (1.9 +/‐ 0.6%) and 3rd (2.0 +/‐ 0.6%) day after stroke onset
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Platelet-derived microparticles measured on the 3rd (13.0 +/‐ 3.0%) day after stroke onset
Number of subjects: 50
Study: 8616303

Group type: EXPERIMENTAL
Intervention: Unsaturated margarine
Number of subjects: 49

Group type: COMPARATOR
Intervention: Butter
Number of subjects: 49
Study: 1600261

Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 36

Group type: COMPARATOR
Intervention: Trichlormethiazide
Number of subjects: 36

Group type: COMPARATOR
Intervention: Comparison of Enalapril vs Trichlormethiazide
Number of subjects: 36
Study: 3903787

Group type: COMPARATOR
Intervention: Ranitidine (0.6 g per day)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Triletide (2 g per day)
Number of subjects: 20
Study: 30736704

Group type: EXPERIMENTAL
Intervention: Affective mental contrasting condition
Number of subjects: 110

Group type: COMPARATOR
Intervention: Instrumental mental contrasting condition
Number of subjects: 110

Group type: COMPARATOR
Intervention: Standard mental contrasting intervention
Number of subjects: 110
Study: 30007401

Group type: EXPERIMENTAL
Intervention: Warm lunch meal with a variety of vegetables, 3 days a week for 3 months
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Warm lunch meal with a variety of vegetables + pedagogical tools (sensory lessons, meal practice advice)
Number of subjects: 210

Group type: COMPARATOR
Intervention: Usual meal practices
Number of subjects: 210
Study: 26359711

Group type: EXPERIMENTAL
Intervention: TY-51924
Number of subjects: 105

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 105
Study: 25226857

Group type: EXPERIMENTAL
Intervention: Controlled ovarian hyperstimulation (COH) - IUI for group 2A (FSH 10-15 mIU/mL and E2<40 pg/mL)
Number of subjects: 603

Group type: EXPERIMENTAL
Intervention: Controlled ovarian hyperstimulation (COH) - IUI for group 2B (FSH 10-15 mIU/mL and E2≥40 pg/mL)
Number of subjects: 603

Group type: EXPERIMENTAL
Intervention: IVF for group 2B (FSH 10-15 mIU/mL and E2≥40 pg/mL)
Number of subjects: 603

Group type: EXPERIMENTAL
Intervention: Basal FSH of 10-15 mIU/mL and E2≥40 pg/mL
Number of subjects: 603
Study: 23756586

Group type: EXPERIMENTAL
Intervention: Walnut-enriched diet (56 g of walnuts daily)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control diet without walnuts
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Walnut-enriched diet
Number of subjects: 46
Study: 19834690

Group type: EXPERIMENTAL
Intervention: Apomorphine sublingually (2 mg)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Apomorphine subcutaneously (0.005 mg/kg)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Apomorphine (subcutaneously)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 17654304

Group type: EXPERIMENTAL
Intervention: INS50589 (0.1-3 mg/kg/h for four hours)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 16029400

Group type: EXPERIMENTAL
Intervention: Sevoflurane-remifentanil
Number of subjects: 22

Group type: COMPARATOR
Intervention: Isoflurane-remifentanil
Number of subjects: 22
Study: 13129878

Group type: EXPERIMENTAL
Intervention: Routine users of aspirin
Number of subjects: 19283

Group type: EXPERIMENTAL
Intervention: Routine users of warfarin
Number of subjects: 19283

Group type: EXPERIMENTAL
Intervention: Discontinued aspirin use
Number of subjects: 19283

Group type: EXPERIMENTAL
Intervention: Discontinued warfarin use
Number of subjects: 19283

Group type: EXPERIMENTAL
Intervention: Routine continuous users of aspirin
Number of subjects: 19283

Group type: EXPERIMENTAL
Intervention: Routine continuous users of warfarin
Number of subjects: 19283
Study: 10383509

Group type: EXPERIMENTAL
Intervention: Cisapride 20 mg b.d.
Number of subjects: 122

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 122
Study: 8867868

Group type: EXPERIMENTAL
Intervention: Orofacial TD
Number of subjects: 266

Group type: EXPERIMENTAL
Intervention: Limbtruncal TD
Number of subjects: 266

Group type: EXPERIMENTAL
Intervention: Preclinical dyskinesia
Number of subjects: 266

Group type: EXPERIMENTAL
Intervention: History of alcohol abuse or dependence
Number of subjects: 266

Group type: EXPERIMENTAL
Intervention: Tremor
Number of subjects: 266
Study: 2066053

Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (500 mg t.i.d.)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 6316289

Group type: EXPERIMENTAL
Intervention: Ketoconazole treatment (daily doses ranged from 3 to 13 mg/Kg, treatment period from 7 days to 14 months)
Number of subjects: 21
Study: 29374667

Group type: EXPERIMENTAL
Intervention: Epidural bupivacaine infusion
Number of subjects: 150

Group type: COMPARATOR
Intervention: No epidural infusion
Number of subjects: 150
Study: 27253224

Group type: EXPERIMENTAL
Intervention: Bevacizumab (BEV) alone or in combination with chemo- and/or radiotherapy
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Bevacizumab (BEV)
Number of subjects: 9
Study: 24902456

Group type: EXPERIMENTAL
Intervention: Propofol plus fentanyl
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Midazolam plus fentanyl
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Propofol alone
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Fentanyl (in both propofol plus fentanyl and midazolam plus fentanyl groups)
Number of subjects: 96
Study: 22361918

Group type: EXPERIMENTAL
Intervention: Landiolol
Number of subjects: 71

Group type: COMPARATOR
Intervention: Diltiazem
Number of subjects: 71
Study: 20427750

Group type: EXPERIMENTAL
Intervention: Pregabalin
Number of subjects: 98

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98
Study: 18657674

Group type: EXPERIMENTAL
Intervention: 64-slice cardiac MDCT
Number of subjects: 268

Group type: COMPARATOR
Intervention: Conventional diagnostic strategy
Number of subjects: 268
Study: 16248236

Group type: EXPERIMENTAL
Intervention: Maiwei Dihuang Oral Liquid (MDOL) 10 ml twice daily for 3 months
Number of subjects: 60

Group type: COMPARATOR
Intervention: Prednisone initial dose of 0.5-1 mg/kg, reduced conditionally over 6-8 weeks
Number of subjects: 60
Study: 12842525

Group type: EXPERIMENTAL
Intervention: ENOX < 12
Number of subjects: 161

Group type: COMPARATOR
Intervention: ENOX
Number of subjects: 161
Study: 10971320

Group type: EXPERIMENTAL
Intervention: Clindamycin 1%/tretinoin 0.025% gel (CTG; Velac) applied once daily
Number of subjects: 100

Group type: COMPARATOR
Intervention: Clindamycin 1% lotion (CLN; Dalacin T) applied twice daily
Number of subjects: 100
Study: 8842578

Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Written examination
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Heat exposure (sauna at 66 degrees C for 40 min)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cold exposure (4 degrees C for 40 min)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control levels (baseline)
Number of subjects: 0
Study: 1518664

Group type: EXPERIMENTAL
Intervention: Cimetidine (7-day administration)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Famotidine (7-day administration)
Number of subjects: 0
Study: 6481665

Group type: EXPERIMENTAL
Intervention: Thematic time-limited groups
Number of subjects: 24
Study: 31163241

Group type: EXPERIMENTAL
Intervention: Adalimumab
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Phototherapy
Number of subjects: 97

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 97
Study: 31645451

Group type: EXPERIMENTAL
Intervention: etokimab (ANB020), an IgG1 anti-IL-33 monoclonal antibody, single systemic administration
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: etokimab (ANB020)
Number of subjects: 12
Study: 29798192

Group type: EXPERIMENTAL
Intervention: APP (application) used in addition to standard discharge instruction
Number of subjects: 144

Group type: COMPARATOR
Intervention: Standard discharge instruction
Number of subjects: 144
Study: 25466666

Group type: EXPERIMENTAL
Intervention: Glutamine (30 g/d)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study: 23839157

Group type: EXPERIMENTAL
Intervention: Attenuated RIX4414 human rotavirus vaccine
Number of subjects: 112

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Both vaccinees and placebo recipients
Number of subjects: 112
Study: 21145269

Group type: EXPERIMENTAL
Intervention: Early endovascular aortic aneurysm repair (EVAR)
Number of subjects: 360

Group type: COMPARATOR
Intervention: Surveillance
Number of subjects: 360
Study: 18650162

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Observation/no adjuvant chemotherapy
Number of subjects: 0
Study: 16569044

Group type: EXPERIMENTAL
Intervention: Lyc‐o‐Mato (5.7 mg of lycopene, 3.7 mg of phytoene, 2.7 mg of phytofluene, 1 mg of beta‐carotene, and 1.8 mg of alpha‐tocopherol)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo drink (same taste and flavor, but devoid of active compounds)
Number of subjects: 26
Study: 12518122

Group type: EXPERIMENTAL
Intervention: Glyceryl trinitrate patch (15 mg)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Placebo patch (control group)
Number of subjects: 144
Study: 11144400

Group type: EXPERIMENTAL
Intervention: Cefdinir 7 mg/kg twice daily or 14 mg/kg once daily for 10 days or 7 mg/kg twice daily for 5 days
Number of subjects: 1274

Group type: COMPARATOR
Intervention: Penicillin V 10 mg/kg 4 times daily for 10 days
Number of subjects: 1274
Study: 9301496

Group type: COMPARATOR
Intervention: RBC 400 mg twice daily alone (RBC400)
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: RBC 400 mg twice daily co‐prescribed with clarithromycin 250 mg four times daily for 14 days (RBC400+CLAR)
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: RBC 800 mg twice daily co‐prescribed with clarithromycin 250 mg four times daily for 14 days (RBC800+CLAR)
Number of subjects: 232
Study: 8472526

Group type: EXPERIMENTAL
Intervention: Cisapride effervescent granules (3 sachets daily for 8 weeks)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Metoclopramide-dimeticone combination (3 sachets daily for 8 weeks)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Cisapride effervescent granules
Number of subjects: 20

Group type: COMPARATOR
Intervention: Metoclopramide-dimeticone combination
Number of subjects: 20
Study: 3464876

Group type: EXPERIMENTAL
Intervention: Diflunisal, naproxen, sulindac (short acting NSAIDs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Piroxicam (long acting NSAID)
Number of subjects: 0
Study: 28195977

Group type: EXPERIMENTAL
Intervention: Fat Grip (FG) training
Number of subjects: 10

Group type: COMPARATOR
Intervention: Normal diameter grip (CON) training
Number of subjects: 10
Study: 27537687

Group type: EXPERIMENTAL
Intervention: Group Support Lifestyle Modification (GSLiM)
Number of subjects: 194

Group type: COMPARATOR
Intervention: Dietary counseling
Number of subjects: 194
Study: 24430917

Group type: EXPERIMENTAL
Intervention: Nabiximols (maximum daily dose, 86.4 mg of Δ9‐tetrahydrocannabinol and 80 mg of cannabidiol)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Nabiximols
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study: 22866361

Group type: EXPERIMENTAL
Intervention: Supportive nursing intervention including BP education sessions, monitoring, goal setting, and reinforcement over 12 weeks with a 30-day follow-up.
Number of subjects: 118

Group type: COMPARATOR
Intervention: Standard care (Control group)
Number of subjects: 118